These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 32757044)
41. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR; Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457 [TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Inderjeeth CA; Foo AC; Lai MM; Glendenning P Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909 [TBL] [Abstract][Full Text] [Related]
43. Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates. Sousa IO; Diniz ET; Marques TF; Griz L; Coutinho Mde A; Bandeira F Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):244-9. PubMed ID: 20485916 [TBL] [Abstract][Full Text] [Related]
44. Bisphosphonates and risk of cardiovascular events: a meta-analysis. Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398 [TBL] [Abstract][Full Text] [Related]
45. Continuous broad protection against osteoporotic fractures with strontium ranelate. Ferrari S Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590 [TBL] [Abstract][Full Text] [Related]
46. Vitamin D supplementation and strontium ranelate absorption in postmenopausal women with low bone mass. Vilaça T; Camargo MB; Rocha OF; Lazaretti-Castro M Eur J Endocrinol; 2014 Apr; 170(4):469-75. PubMed ID: 24394724 [TBL] [Abstract][Full Text] [Related]
47. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. Farlay D; Boivin G; Panczer G; Lalande A; Meunier PJ J Bone Miner Res; 2005 Sep; 20(9):1569-78. PubMed ID: 16059629 [TBL] [Abstract][Full Text] [Related]
48. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. Etminan M; Aminzadeh K; Matthew IR; Brophy JM J Rheumatol; 2008 Apr; 35(4):691-5. PubMed ID: 18203310 [TBL] [Abstract][Full Text] [Related]
49. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495 [TBL] [Abstract][Full Text] [Related]
50. Osseointegration effects of local release of strontium ranelate from implant surfaces in rats. Alenezi A; Galli S; Atefyekta S; Andersson M; Wennerberg A J Mater Sci Mater Med; 2019 Oct; 30(10):116. PubMed ID: 31606798 [TBL] [Abstract][Full Text] [Related]
51. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. Johannesdottir SA; Horváth-Puhó E; Dekkers OM; Cannegieter SC; Jørgensen JO; Ehrenstein V; Vandenbroucke JP; Pedersen L; Sørensen HT JAMA Intern Med; 2013 May; 173(9):743-52. PubMed ID: 23546607 [TBL] [Abstract][Full Text] [Related]
52. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate. Cortet B Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589 [TBL] [Abstract][Full Text] [Related]
53. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Reginster JY; Deroisy R; Jupsin I Drugs Today (Barc); 2003 Feb; 39(2):89-101. PubMed ID: 12698204 [TBL] [Abstract][Full Text] [Related]
54. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203 [TBL] [Abstract][Full Text] [Related]
55. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Hiligsmann M; Bruyère O; Reginster JY Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940 [TBL] [Abstract][Full Text] [Related]
56. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789 [TBL] [Abstract][Full Text] [Related]
57. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755 [TBL] [Abstract][Full Text] [Related]
58. [Strontium ranelate: a novel concept for the treatment of osteoporosis]. Dimai HP Wien Klin Wochenschr; 2005 Nov; 117(21-22):728-38. PubMed ID: 16416353 [TBL] [Abstract][Full Text] [Related]
59. [The combined use of bisphosphonates and strontium ranelate with osseosubstituting materials]. Khlusov IA; Vengerovsky AI; Novitsky VV Vestn Ross Akad Med Nauk; 2014; (11-12):128-32. PubMed ID: 25971138 [TBL] [Abstract][Full Text] [Related]
60. Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? Vestergaard P Calcif Tissue Int; 2012 Jan; 90(1):22-9. PubMed ID: 22120197 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]